Levodopa/Carbidopa
FDA Approved
Description
Levodopa/Carbidopa is a dopamine precursor combination used primarily for Parkinson's disease. It has been utilized off-label for certain neurologic defects and movement disorders associated with rare genetic syndromes. The combination increases dopamine availability in the central nervous system to improve motor function.
Indications & Therapeutic Use
Parkinson's disease, parkinsonism, restless legs syndrome, neurologic movement disorders
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Levodopa/Carbidopa
| Generic Name | Levodopa/Carbidopa |
| Brands | 1 brand available |
| Active Ingredient | Levodopa and Carbidopa |
| Drug Class | Parkinson's disease |
| Manufacturer | Merck & Co. |
| Dosage Forms | Oral tablet, various combinations (25/100mg, 25/250mg); Extended-release tablet |
| Medical Code | N04BA02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes